经内镜逆行胰胆管造影术后胰腺炎研究进展
Research Progress of Pancreatitis after Endoscopic Retrograde Cholangiopancreatography
摘要: 胰腺炎是经内镜逆行胰胆管造影术(ERCP)术后最常见的并发症，在ERCP发展的几十年中一直有着较高的发病率，严重影响患者的术后恢复。本文综述了术后胰腺炎的发病机制、危险因素以及用于预防及术后胰腺炎的各种药物和手术方法，以改善内窥镜逆行胰胆管造影术后患者的预后。
Abstract: Pancreatitis is the most common complication after Endoscopic Retrograde Cholangiopancreatography (ERCP). It has a high incidence rate in the decades of ERCP development, which seriously affects the postoperative recovery of patients. This article reviews the pathogenesis, risk factors, and various drugs and surgical methods used for the prevention and treatment of postoperative pancreatitis, to improve the prognosis of patients after endoscopic retrograde cholangiopancreatography.
文章引用：朱成龙, 陈俊卯. 经内镜逆行胰胆管造影术后胰腺炎研究进展[J]. 亚洲急诊医学病例研究, 2025, 13(1): 103-108. https://doi.org/10.12677/acrem.2025.131016

参考文献

[1] 中华医学会消化内镜分会ERCP学组. 内镜下逆行胆胰管造影术(ERCP)诊治指南(2010版) [J]. 中国继续医学教育, 2010, 2(6): 1-20.
[2] 李鹏, 王拥军, 王文海. 中国经内镜逆行胰胆管造影术指南(2018版) [J]. 临床肝胆病杂志, 2018(12): 2537-2554.
[3] Obeidat, A.E., Mahfouz, R., Monti, G., Kozai, L., Darweesh, M., Mansour, M.M., et al. (2022) Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: What We Already Know. Cureus, 14, e21773. [Google Scholar] [CrossRef] [PubMed]
[4] Cotton, P.B., Lehman, G., Vennes, J., Geenen, J.E., Russell, R.C.G., Meyers, W.C., et al. (1991) Endoscopic Sphincterotomy Complications and Their Management: An Attempt at Consensus. Gastrointestinal Endoscopy, 37, 383-393. [Google Scholar] [CrossRef] [PubMed]
[5] Banks, P.A., Bollen, T.L., Dervenis, C., Gooszen, H.G., Johnson, C.D., Sarr, M.G., et al. (2012) Classification of Acute Pancreatitis—2012: Revision of the Atlanta Classification and Definitions by International Consensus. Gut, 62, 102-111. [Google Scholar] [CrossRef] [PubMed]
[6] Ribeiro, I.B., do Monte Junior, E.S., Miranda Neto, A.A., Proença, I.M., de Moura, D.T.H., Minata, M.K., et al. (2021) Pancreatitis after Endoscopic Retrograde Cholangiopancreatography: A Narrative Review. World Journal of Gastroenterology, 27, 2495-2506. [Google Scholar] [CrossRef] [PubMed]
[7] Noble, M.D., Romac, J., Vigna, S.R. and Liddle, R.A. (2008) A Ph-Sensitive, Neurogenic Pathway Mediates Disease Severity in a Model of Post-ERCP Pancreatitis. Gut, 57, 1566-1571. [Google Scholar] [CrossRef] [PubMed]
[8] Chen, J., Wang, X., Liu, X., Li, W., Dong, M., Suo, Z., et al. (2014) Risk Factors for Post-ERCP Pancreatitis: A Systematic Review of Clinical Trials with a Large Sample Size in the Past 10 Years. European Journal of Medical Research, 19, Article No. 26. [Google Scholar] [CrossRef] [PubMed]
[9] Hauser, G. (2015) Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: What Can Be Done? World Journal of Gastroenterology, 21, 1069-1080. [Google Scholar] [CrossRef] [PubMed]
[10] Ito, K., Fujita, N., Kanno, A., Matsubayashi, H., Okaniwa, S., Nakahara, K., et al. (2011) Risk Factors for Post-ERCP Pancreatitis in High Risk Patients Who Have Undergone Prophylactic Pancreatic Duct Stenting: A Multicenter Retrospective Study. Internal Medicine, 50, 2927-2932. [Google Scholar] [CrossRef] [PubMed]
[11] Saito, H., Fujimoto, A., Oomoto, K., Kadowaki, Y. and Tada, S. (2022) Current Approaches and Questions Yet to Be Resolved for the Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis. World Journal of Gastrointestinal Endoscopy, 14, 657-666. [Google Scholar] [CrossRef] [PubMed]
[12] Song, Y. and Lee, S. (2024) Recent Treatment Strategies for Acute Pancreatitis. Journal of Clinical Medicine, 13, Article No. 978. [Google Scholar] [CrossRef] [PubMed]
[13] Radadiya, D., Devani, K., Arora, S., Charilaou, P., Brahmbhatt, B., Young, M., et al. (2019) Peri-Procedural Aggressive Hydration for Post Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis Prophylaxsis: Meta-Analysis of Randomized Controlled Trials. Pancreatology, 19, 819-827. [Google Scholar] [CrossRef] [PubMed]
[14] Wu, B.U., Hwang, J.Q., Gardner, T.H., Repas, K., Delee, R., Yu, S., et al. (2011) Lactated Ringer’s Solution Reduces Systemic Inflammation Compared with Saline in Patients with Acute Pancreatitis. Clinical Gastroenterology and Hepatology, 9, 710-717.e1. [Google Scholar] [CrossRef] [PubMed]
[15] Messallam, A.A., Body, C.B., Berger, S., Sakaria, S.S. and Chawla, S. (2021) Impact of Early Aggressive Fluid Resuscitation in Acute Pancreatitis. Pancreatology, 21, 69-73. [Google Scholar] [CrossRef] [PubMed]
[16] Wang, G., Xiao, G., Xu, L., Qiu, P., Li, T., Wang, X., et al. (2018) Effect of Somatostatin on Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis and Hyperamylasemia: A Systematic Review and Meta-Analysis. Pancreatology, 18, 370-378. [Google Scholar] [CrossRef] [PubMed]
[17] Wang, J., Shen, Y., Zhong, Z., Wu, S. and Zheng, L. (2018) Risk Factors for Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis and the Effect of Octreotide Combined with Nonsteroidal Anti-Inflammatory Drugs on Preventing Its Occurrence. Medical Science Monitor, 24, 8964-8969. [Google Scholar] [CrossRef] [PubMed]
[18] Li, L., Liu, M., Zhang, T., Jia, Y., Zhang, Y., Yuan, H., et al. (2019) Indomethacin Down-Regulating HMGB1 and TNF-Α to Prevent Pancreatitis after Endoscopic Retrograde Cholangiopancreatography. Scandinavian Journal of Gastroenterology, 54, 793-799. [Google Scholar] [CrossRef] [PubMed]
[19] Geng, C., Li, X., Li, Y., Song, S. and Wang, C. (2020) Nonsteroidal Anti‐Inflammatory Drugs Alleviate Severity of Post‐endoscopic Retrograde Cholangiopancreatography Pancreatitis by Inhibiting Inflammation and Reducing Apoptosis. Journal of Gastroenterology and Hepatology, 35, 896-904. [Google Scholar] [CrossRef] [PubMed]
[20] Serrano, J., de Moura, D., Bernardo, W., Ribeiro, I., Franzini, T., de Moura, E., et al. (2019) Nonsteroidal Anti-Inflammatory Drugs versus Placebo for Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Systematic Review and Meta-Analysis. Endoscopy International Open, 7, E477-E486. [Google Scholar] [CrossRef] [PubMed]
[21] Ahmad, W., Okam, N.A., Torrilus, C., Rana, D., Khatun, M.K. and Jahan, N. (2020) Pharmacological Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: Where Do We Stand Now? Cureus, 12, e10115. [Google Scholar] [CrossRef] [PubMed]
[22] Dumonceau, J., Kapral, C., Aabakken, L., Papanikolaou, I.S., Tringali, A., Vanbiervliet, G., et al. (2019) ERCP-Related Adverse Events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 52, 127-149. [Google Scholar] [CrossRef] [PubMed]
[23] Yuhara, H., Ogawa, M., Kawaguchi, Y., Igarashi, M., Shimosegawa, T. and Mine, T. (2013) Pharmacologic Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: Protease Inhibitors and NSAIDs in a Meta-Analysis. Journal of Gastroenterology, 49, 388-399. [Google Scholar] [CrossRef] [PubMed]
[24] 柏愚, 李德锋, 王树玲, 等. 经内镜逆行胰胆管造影术围手术期用药专家共识意见[J]. 临床肝胆病杂志, 2018(12): 2555-2562.
[25] Yu, G., Li, S., Wan, R., Wang, X. and Hu, G. (2015) Nafamostat Mesilate for Prevention of Post-ERCP Pancreatitis: A Meta-Analysis of Prospective, Randomized, Controlled Trials. Pancreas, 44, 561-569. [Google Scholar] [CrossRef] [PubMed]
[26] Horváth, I.L., Kleiner, D., Nagy, R., Fehérvári, P., Hankó, B., Hegyi, P., et al. (2023) Nafamostat Reduces the Incidence of Post‐ERCP Pancreatitis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Clinical Pharmacology & Therapeutics, 115, 206-212. [Google Scholar] [CrossRef] [PubMed]
[27] Kim, J.S., Lee, S.H., Park, N., Huh, G., Chun, J.W., Choi, J.H., et al. (2022) The Effect of Nafamostat Mesilate Infusion after ERCP for Post-ERCP Pancreatitis. BMC Gastroenterology, 22, Article No. 271. [Google Scholar] [CrossRef] [PubMed]
[28] Li, C., Ma, D., Chen, M., Zhang, L., Zhang, L., Zhang, J., et al. (2016) Ulinastatin Attenuates LPS-Induced Human Endothelial Cells Oxidative Damage through Suppressing Jnk/c-Jun Signaling Pathway. Biochemical and Biophysical Research Communications, 474, 572-578. [Google Scholar] [CrossRef] [PubMed]
[29] 杨超, 单爱军, 钟源波. 乌司他汀对急性重症胰腺炎大鼠NF-κB活性NF-κB mRNA表达的实验研究[J]. 检验医学与临床, 2014, 11(12): 1620-1622.
[30] 周海鸥, 余跃, 施燕, 等. 不同剂量乌司他汀对急性胰腺炎患者血清TNFα, IL-1, IL-6及IL-8水平的影响[J]. 现代生物医学进展, 2017, 17(21): 4096-4099.
[31] Muili, K.A., Wang, D., Orabi, A.I., Sarwar, S., Luo, Y., Javed, T.A., et al. (2013) Bile Acids Induce Pancreatic Acinar Cell Injury and Pancreatitis by Activating Calcineurin. Journal of Biological Chemistry, 288, 570-580. [Google Scholar] [CrossRef] [PubMed]
[32] Barakat, M.T., Khalid, A., Yu, M., Ding, Y., Murayi, J., Jayaraman, T., et al. (2022) A Review of the Rationale for the Testing of the Calcineurin Inhibitor Tacrolimus for Post-ERCP Pancreatitis Prevention. Pancreatology, 22, 678-682. [Google Scholar] [CrossRef] [PubMed]
[33] Tomoda, T., Kato, H., Ueki, T., Akimoto, Y., Hata, H., Fujii, M., et al. (2019) Combination of Diclofenac and Sublingual Nitrates Is Superior to Diclofenac Alone in Preventing Pancreatitis after Endoscopic Retrograde Cholangiopancreatography. Gastroenterology, 156, 1753-1760.e1. [Google Scholar] [CrossRef] [PubMed]
[34] Aletaha, N., Hamid, H., Alipour, A. and Ketabi Moghadam, P. (2022) Magnesium Sulfate for Prevention of Post-ERCP-Pancreatitis: A Randomized Controlled Trial. Archives of Iranian Medicine, 25, 148-154. [Google Scholar] [CrossRef] [PubMed]
[35] 杜力巍, 田笑笑, 白艳丽. 硫酸镁对ERCP术后发生急性胰腺炎的预防作用[J]. 胃肠病学和肝病学杂志, 2023(11): 1258-1261.

为你推荐